Alemtuzumab more effective than interferon β-1a at 5-years

A board to discuss the soon-to-be released drug Campath as a treatment for Multiple Sclerosis

Alemtuzumab more effective than interferon β-1a at 5-years

Postby MSUK » Tue Mar 27, 2012 11:33 pm

Alemtuzumab more effective than interferon β-1a at 5-year follow-up


Summary: The authors present 5-year follow-up data from the CAMMS223 study, reporting on the long-term safety and efficacy of alemtuzumab treatment compared with interferon β-1a in early, active relapsing-remitting multiple sclerosis (RRMS). Over 5 years, alemtuzumab lowered the risk of sustained accumulation of disability by 72%. The annualised relapse rate over the 5 years was 0.11 for alemtuzumab and 0.35 for IFNβ-1a.

Most commonly occurring serious side effects were serious infections occurring in 7% of alemtuzumab treated patients, with 30% developing thyroid problems (compared to only 4% in IFNβ-1a group).

The study shows good evidence for the efficacy in reducing progression of disability and relapse rate reduction in patients with RRMS compared with IFNβ-1a and side effect profile in line with previously published data....Read More - ... ageid/1307
User avatar
Family Elder
Posts: 2903
Joined: Wed Oct 14, 2009 2:00 pm


Return to Campath (Lemtrada, Alemtuzumab)


  • Related topics
    Last post

Who is online

Users browsing this forum: No registered users

Contact us | Terms of Service